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Carcinoma cells lack syndecan-1 expression when they are transiting from an epithelial to a less-differentiated mesenchymal
phenotype (epithelial–mesenchymal transition, EMT). Furthermore, a shift of syndecan-1 expression from malignant epithelial cells to
reactive stromal cells has also been observed during progression of many carcinomas. Finally, epithelial and/or stromal syndecan-1
expression is of prognostic value in many carcinomas. Because recent results are contradictory in breast carcinomas, we have
re-evaluated the prognostic significance of syndecan-1 expression in a cohort of 80 patients with invasive ductal breast carcinomas.
The tumours from 80 patients diagnosed with invasive ductal breast carcinomas were used to construct a tissue microarray, which
was stained with syndecan-1 by immunohistochemistry. We correlated syndecan-1 expression with clinicopathologic parameters and
relapse-free survival (RFS). Exclusive epithelial expression of syndecan-1 is observed in 61.25% of the patients, whereas exclusive
stromal expression is observed in 30% of the patients. Only 8.75% of the patients had both stromal and epithelial expressions of
syndecan-1. A significant correlation was found between the loss of syndecan-1 epithelial expression and the syndecan-1 stromal
expression with high grade of malignancy (P¼0.011). The loss of syndecan-1 epithelial expression is correlated with RFS (P¼0.001).
Using multivariate Cox analysis, loss of epithelial syndecan-1 expression was the only prognostic indicator (Po0.001). We concluded
that the loss of syndecan-1 epithelial expression was of strong prognostic value in breast carcinomas.
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Syndecan-1, a transmembrane heparan sulphate proteoglycan, is
expressed by many normal cells, including epithelial and
endothelial cells. It is also expressed in carcinoma cells.
Syndecan-1 is an antigen of differentiation that is lost by
carcinoma cells when these malignant cells are transiting from
an epithelial to a less-differentiated mesenchymal phenotype
(epithelial–mesenchymal tumoral transition, EMT) (Kato et al,
1995; Leppa ¨ et al, 1996 and reviewed in Larue and Bellacosa, 1996).
Of major interest, a shift of syndecan-1 expression from malignant
epithelial cells to reactive stromal cells has also been observed in
many carcinomas during their progression (Mennerich et al,
2004). Epithelial and/or stromal syndecan-1 expression is of
prognostic value in many carcinomas, but because recent results
are contradictory in breast carcinomas (Barbareschi et al, 2003;
Leivonen et al, 2004), we have re-evaluated the prognostic
significance of syndecan-1 expression in a homogeneous cohort
of patients with invasive ductal breast carcinomas.
PATIENTS AND METHODS
Patients
We included 80 patients with breast cancer, considered as good
prognosis, between January 1995 and December 2001 at the Rene ´
Gauducheau Comprehensive Cancer Center (Nantes, France),
according to the following criteria: no chemotherapy in adjuvant
and neoadjuvant setting, histological diagnosis of invasive ductal
carcinoma, no pathological lymph node invasion, no distant
metastasis, no other previous or concomitant primary malignan-
cies. The mean age was 72.7 years (44–95 years). The main
clinicopathological features are listed in Table 1. Patients were
staged according to the International Union against Cancer Node
Metastasis (UICC-TNM) Classification. All patients underwent
tumorectomy (n¼65) or mastectomy (n¼15) with auxillary
lymph node dissection. Seventy-four patients (92.5%) received
post-operative irradiation and 66 (82.5%) hormone therapy. The
patients who did not receive hormone therapy were those
presenting with a contre-indication. None of these patients
received chemotherapy in adjuvant or neoadjuvant setting. The
median follow-up among survivors was 7.1 years (range, 4.5–9.9
years).
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Tissue specimen was fixed in 10% buffered formalin and routinely
processed. Tumour grading was performed according to
Scarff–Bloom–Richardson grading modified by Elston and Ellis
(1991).
The arrays were constructed with the 1mm punch of the
Beecher arrayer. Haemalun–eosin–safran-stained sections of
breast ductal invasive carcinoma were reviewed and the area of
interest marked out on the slide. This area of interest corre-
sponded to both stroma and carcinoma cells. Three cores with a
diameter of 1mm were punched out from the paraffin-embedded
tissue block in each case and incorporated into a final tissue array
block. A control tissue sample (normal breast) was included in the
final array block.
Before immunostaining, an HES-stained section of the final
array block was examined to confirm the representative areas of
the tumours in comparison with the original HES-stained section.
Immunohistochemistry
Sections (4mm) were cut from the tissue microarray blocks and
placed on superfrost slides. The immunochemical technique was
performed on an automated immunostainer (Lab Vision, Fremont,
USA) using the streptavidin–biotin amplification technique
(ChemMate kit; Dako, Glostrup, Denmark) after appropriate
antigen retrieval in EDTA buffer (pH 8) at 951C. It involved the
application of the specific primary antibodies to Syndecan-1/
CD138 (clone MI15, dilution 1:100; Dako), estrogen receptor
(6F11, 1:100; Novocastra, Newcastle, UK), progesterone receptor
(PgR636, 1:100; Dako), and HER2 (1:800; Dako). Peroxidase
activity was revealed using 3,30-diaminobenzidine for 5min.
Sections were counterstained with Harris haematoxylin for
3min. Negative controls were obtained by omitting primary
antibodies. Positive internal controls were normal ducts.
Immunohistochemistry interpretation
Immunohistochemical staining was assessed in both epithelial and
stromal components. The proportion of cells stained as well as the
intensity of staining was evaluated. The percentage of imuno-
reactive carcinoma cells was evaluated by two observers.
Syndecan-1 immunostaining intensity (of the carcinoma cells
and stroma) was scored as follows: 0, no staining; 1þ, weak; 2þ,
moderate; 3þ, strong. The level of epithelial immunostaining was
graded by scoring the percentage of syndecan-1-positive carcino-
ma cells into two groups as negative (o10% of the cancer cells
positive) and positive (410% carcinoma cells positive).
The level of stromal immunostaining was graded by scoring the
percentage of positivity into two groups: negative (o10%) and
positive (410%).
Statistical analysis
Categorical data, presented as frequencies, were compared using
the Fisher exact test and continuous variables, expressed as
median (range) was compared using the Mann–Whitney or the
Kruskal–Wallis test as appropriate. Event for disease-free survival
was relapse (local or distant). Relapse-free survival (RFS) curves
were estimated using the Kaplan–Meier method and compared at
univariate step by the means of log-rank tests. Cox proportional
hazards regression analyses were performed on epithelial expres-
sion (discretized and continuous) and on all other known
prognostic parameters to assess the independent association of
them to RFS. Because of the small number of relapses during
follow-up (n¼13/80), we were concerned about the possibility of
model overfitting. To confirm the results obtained on the original
data set, we decided to use permutation test at the univariate step
and bootstrapping techniques at the multivariate step. In
univariate analysis, we determined for each parameter from
10000 new data sets derived from random permutation sampling
the probability that new P-value was greater than that from the
original data set. In multivariate analysis, we created 10000 new
data sets derived from random bootstrap sampling and replace-
ment of the main cohort set, and we performed a stepwise Cox
regression analysis on each data set. We counted the number of
models each of the parameters entered (10000 possible) and
estimated the distribution of b-coefficients (median, range) if a
parameter was present in more than a half of simulations. In order
to obtain very extreme values, range was expressed from 1st
percentile to 99th percentile. All data were analysed with SAS
version 9.1 (SAS Institute, Cary, NC, USA) and STATA 8.2 SE
(StataCorp, College Station, TX, USA).
RESULTS
Syndecan-1 expression
Intense staining on the basolateral surface of epithelial cells from
normal ducts demonstrates characteristic localisation of syndecan-
1. No immunostaining was observed in normal stromal tissue.
Syndecan-1 expression in breast carcinoma specimen was
observed in epithelial tumour cells, stromal component, or both.
Both epithelial and stromal components showed a very homo-
geneous staining. Only epithelial syndecan-1 immunostaining was
observed in 49 out of 80 patients (61.25%) (Figure 1A). The
median percentage of positive carcinoma cells was 100% (range:
Table 1 Baseline characteristics of 80 patients according to syndecan-1
epithelial and/or stromal expression
Variable
E+ (S+ou )
n¼56
E  (S+)
n¼24 P-value
Age (years)
Median 73 76
Range (44–95) (50–91) 0.194
Histologic size (mm)
Median 20 21
Range (10–40) (7–35) 0.458
pT
pT1 32 12
pT2 24 12 0.628
EE grade
I2 0 2
II 30 15
III 6 7 0.011
ER
+5 3 2 4
  3 0 0.550
PR
+4 7 2 0
  9 4 1.000
Hormone therapy
No 10 4
Yes 46 20 1.000
HER2
0, 1, 2 + 54 23
3+ 2 1 1.000
E¼epithelial staining (E+¼56 patients, E ¼24 patients); EE grade¼Elston and
Ellis grade; ER¼oestrogen receptor; PR¼progesterone receptor; S¼stromal
staining.
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stromal expression in 7 out of 80 patients (8.75%) (Figure 1B). In
these cases, the median percentage of positive carcinoma cells was
100% (range: 50–100%). Only stromal syndecan-1 expression was
observed in 24 out of 80 patients (30%) (Figure 1C). Immuno-
staining was seen both in stromal cells and in collagen tissue. The
median percentage of stroma immunoreactivity was 100% (range:
70–100%). In all cases, intensity of epithelial and stromal
immunostaining was strong (3þ).
Syndecan-1 expression correlates
Baseline characteristics of the patients according to their epithelial
expression status were described in Table 1. A high syndecan-1
expression in epithelial tumour cells was strongly associated with
low histological grade (Po0.011). Conversely, the absence of
epithelial expression correlated with the highest histological grade.
Generally, higher levels of syndecan-1 immunostaining were
observed in the well-differentiated tumours, whereas significant
reduction of syndecan-1 immunostaining was observed in poorly
differentiated tumours.
Baseline characteristics and univariate RFS analysis
Median follow-up among survivors was 7.1 years (range, 4.5–9.9
years). There were 13 relapses; 9 metastasis; and 4 local relapses.
At median follow-up (7 years), RFS was not different between
patients with exclusive epithelial expression (EþS ) and patients
with epithelial and stromal expression (Eþ/Sþ) (95.6 vs 100%,
P¼0.54). Patients with exclusive stromal expression (E Sþ) had
7-year RFS significantly lower than patients with exclusive
epithelial expression (EþS ) (55.6 vs 95.6%; Po0.001) or
associated with stromal expression (EþSþ) (36 vs 100%,
P¼0.055). So, EþSþ and EþS  groups were pooled and
analysed compared with the E Sþ group for further analyses
(Figure 2A).
Figure 1 (A) Intense membranous immunostaining of carcinoma cells;
no stromal immunostaining (Eþ/S ). (B) Immunostaining of both
carcinoma cells and stroma (EþSþ). (C) Stromal immunostaining and
no epithelial immunostaining (E Sþ).
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Figure 2 Kaplan–Meier RFS curves according to epithelial status. (A)
Separate epithelium/stroma status. (B) Epithelium positive vs epithelium
negative status.
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found between the loss of epithelial expression and RFS. Patients
with epithelial expression (exclusive or associated with stromal
expression) had excellent outcome (7-year Kaplan–Meier RFS:
96%; 95% CI: 86–99%), whereas patients without epithelial
expression had worse outcome (7-year Kaplan–Meier RFS: 56%;
95% CI: 33–73%) (Figure 2B). No significant association was
found in our population between RFS and the other known
prognostic factors (age, Elston and Ellis grade, histologic tumour
size, pT stage, hormone therapy, and PR or ER status). The result
of the loss of epithelial expression was reinforced by permutation
test (detailed tests results in Table 2).
Multivariate RFS analysis
To confirm accuracy of group repartition (EþSþ and EþS- vs
E Sþ), first Cox analysis on original data set was made only on
the two opposite groups (EþS  vs E Sþ). Comparison of this
restricted model with the other two complete models (model 2:
EþS  and EþSþ vs E Sþ/model 3: EþS  vs EþSþ and
E Sþ) confirmed better fit of model 2 (Eþ vs E ) with restricted
one than model 3 (Sþ vs S ) (data not shown).
On original data set, epithelial expression loss HR was 10.92
(95% CI: 2.8–42.6), with Po0.001 if discretized as E  vs Eþ and
was 13.69 (95% CI: 3.03–61.80), with Po0.001 if continuous. No
other parameter was significantly associated with RFS (Table 3).
The results of 10000 bootstrap-based stepwise Cox proportional
hazards analyses strengthened the independent role of epithelial
expression in RFS and confirmed its HR level: this parameter
entered 8511 models (10000 possible) with a estimate b-median
value of 2.25 (95% CI: 1.21–4.67) (corresponding to HR¼9.52;
95% CI: 3.3–106.3) with a P-value median of 0.0015 (95% CI:
1 10-4 to 0.0304) (Figure 3).
DISCUSSION
The progression of epithelial tumours is characterised by (i) a loss
of syndecan-1 expression in tumour cells (EMT) and (ii) a shift of
syndecan-1 expression from tumour cells to stroma. First, EMT is
the conversion of malignant epithelial cells into cells with a
mesenchymal phenotype (Larue and Bellacosa, 2005). A critical
feature of EMT is the downregulation of both E-cadherin and
syndecan-1 expression on tumour cells (Kato et al, 1995; Leppa ¨
et al, 1996). Second, the expression of syndecan-1 in the stroma is
Table 2 Univariate relapse free log-rank analysis
Variable HR (95% CI) P-value (original set) P-value permutation (n¼10000)
Epithelial expression (negative vs positive) 8.76 (2.41–31.83) 0.001 0.0001
Epithelial expression (continuous) 10.79 (2.50–46.56) 0.001 0.0003
pT stage (pT2 vs pT1) 0.55 (0.17–1.80) 0.324 0.377
Age (years) 0.97 (0.93–1.02) 0.330 0.310
SBR grade
II vs I 1.07 (0.28–4.14) 0.923 1.000
III vs I 1.62 (0.33–8.07) 0.573 0.586
Hormone therapy (yes vs no) 0.67 (0.18–2.47) 0.550 0.562
Her2 (3+ vs 0, 1, 2+) 2.74 (0.35–21.21) 0.334 0.395
PR (negative vs positive) 2.39 (0.73–7.79) 0.148 0.062
ER (negative vs positive) — NC* NC*
ER¼oestrogen receptor; HR¼hazard ratio; PR¼progesterone receptor. *NC, not calculable.
Table 3 Multivariate Cox relapse-free analysis
Variable HR HR 95% CI P-value Bootstrap stepwise Cox (n/10000)
Epithelial status (E  vs E+) 11.43 2.94–44.43 o0.0001 8511
pT stage (pT2 vs pT1) 0.37 0.06–2.34 0.293 2303
Age (years) 0.96 0.91–1.02 0.227 3974
SBR (III vs I, II) 1.97 0.25–15.62 0.521 1573
Hormone therapy (yes vs no) 1.04 0.24–4.50 0.953 640
Her2 (3+ vs 0, 1, 2+) 2.92 0.29–29.93 0.366 1573
PR (negative vs positive) 2.23 0.65–7.72 0.203 3479
ER (negative vs positive) NC* — — —
ER¼oestrogen receptor; HR¼hazard ratio; NC¼not calculable; PR¼progesterone receptor. Number of subjects¼80/number of failures¼13/LR w
2 (7)¼21.15/
Probability4w
2¼0.0036. *NC was dropped for non-convergence.
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Figure 3 Estimate distribution of absence of epithelial expression
(10000 bootstraped data sets).
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scharacterised by the appearance of a strong immunoreactivity for
syndecan-1 in the reactive stroma of invasive carcinomas
(Mennerich et al, 2004). Such stroma immunoreactivity, that
corresponds to a true induction of syndecan-1 synthesis by
reactive stromal cells and not simply to the fixation of shedded
syndecan-1 to stromal cells (Mennerich et al, 2004), has been
initially described in invasive breast carcinomas by Stanley et al,
(1999) and confirmed by others (Wiksten et al, 2001; Mennerich
et al, 2004). Epithelial–mesenchymal transition is associated with
a more aggressive Akt/PI-3K signalling pathway within carcinoma
cells and with clinically more aggressive tumours (Larue and
Bellacosa, 2005). Furthermore, experimental and clinical data have
shown that the expression of syndecan-1 in the stroma promotes
breast carcinoma growth in vivo and stimulates tumour angio-
genesis (Maeda et al, 2004, 2006). In summary, the loss of syndecan-1
by carcinoma cells leads to the appearance of a more aggressive
phenotype and behaviour of carcinoma cells, whereas the
expression of syndecan-1 in the reactive stromal cells creates a
favourable microenvironment for tumour cell growth and
angiogenesis.
In breast carcinomas, three studies have been devoted to the
expression of syndecan-1 (Stanley et al, 1999; Barbareschi et al,
2003; Leivonen et al, 2004). Stanley et al (1999) were the first to
describe the induction of syndecan-1 expression in the stroma of
invasive breast carcinomas, but the small number of patients
(n¼20) did not permit any statistical study. The two other studies
are contradictory. Barbareschi et al (2003) have shown that
syndecan-1 is expressed at high levels in a significant percentage of
breast carcinomas and that this high expression is related to a poor
clinical behaviour. Stromal syndecan-1 expression was not
considered on a prognostic point of view. Leivonen et al (2004)
have also shown the poorer prognosis of breast carcinoma patients
expressing syndecan-1 within their tumour cells, but the better
prognosis of those lacking syndecan-1 expression within the
stroma. Both studies were in disagreement with many other studies
showing that the loss of syndecan-1 expression within carcinoma
cells, rather than its high expression, was of poor prognostic value,
as well as expression of syndecan-1 in the stroma (Mennerich et al,
2004; Larue and Bellacosa, 2005, and more specifically Inki et al,
1994; Matsumoto et al, 1997; Nackaerts et al, 1997; Anttonen et al,
1999; Conejo et al, 2000; Juuti et al, 2005). Finally, both studies
suggested that breast carcinomas could be an exception within
carcinomas.
For these reasons, we have re-evaluated the prognostic value of
syndecan-1 in patients with invasive breast carcinomas. The interest
of our cohort of patients is its homogeneity: one histological type of
breast carcinoma, homogeneity of treatment, especially lack of
chemotherapy, in contrast to the other studies devoted to breast
cancers. Our study shows that 61.25% of our patients with invasive
ductal breast carcinomas overexpressed syndecan-1 within their
carcinoma cells, whereas lacking it in the stroma (EþS ) and that
30% lacked syndecan-1 within the tumour cells but expressed it in
their stroma (E Sþ). Only 8.75% of the patients retained
syndecan-1 expression within their tumour cells while having
reactive stroma-expressing syndecan-1 (EþSþ). This last group of
patients is too small to allow any further investigation and to draw
any conclusion. Our correlates and survival studies have shown that
these two processes correlated with high grade of malignancy and
with poor RFS. In all the cases, however, correlations were
statistically more significant with the loss of syndecan-1 epithelial
expression. Finally, our multivariated analyses have shown that the
loss of syndecan-1 epithelial expression was the strongest prognostic
predictor of survival in these patients. Our data are in agreement
with other studies showing that both loss of syndecan-1 epithelial
expression and syndecan-1 stromal expression are associated with
poor clinical outcome in many cancers and in addition show that
this is also true in cases of invasive ductal breast carcinomas.
Further investigations will be necessary to (i) evaluate more patients
with different histological types of breast carcinomas (and different
types of treatments); (ii) define the gene profiling of these new
different types of patients (EþS ,E - S þ,a n dt h er a r eE þSþ)
in comparison with previously published gene profiling of ductal
carcinomas (Sorlie et al, 2001); and (iii) understand the simulta-
neous or dissociated mechanisms in charge of these processes.
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